Fierce Pharma
JULY 1, 2024
Welcome to Fierce Pharma's regulatory tracker for the second half of 2024. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
David Bagga
JULY 1, 2024
Medical Device Sales Academy What Degree is Best For Medical Sales? The healthcare industry, a significant driver of the economy and a key player in improving people’s lives, is poised for continued growth. This expansion is fueled by the increasing demand for healthcare services and tools, driven by an aging population and prevalent illnesses.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JULY 1, 2024
In yet another legal development surrounding counterfeit HIV drugs, a Florida court has handed down an indictment for the owners of a wholesale distributor that allegedly bought and redistribu | The wholesaler Safe Chain allegedly purchased $90 million of misbranded, diverted and adulterated HIV meds, according to U.S. authorities. The indictment of the company's three owners follows separate lawsuits from Gilead and Johnson & Johnson.
pharmaphorum
JULY 1, 2024
AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).The drugmaker said this morning that an application for sipavibart (AZD3152) has been accepted for review by the EMA as PrEP for immunocompromised patients who often do not respond adequately to vaccination alone and remain at high risk of serious outcomes from COVID-19.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
JULY 1, 2024
GSK scratched another Zantac lawsuit off the list with a confidential settlement in Illinois as it continues to work through the mountain of personal injury litigation related to the heartburn pill | Following a win and a separate dismissal in Illinois, GSK agreed to a confidential settlement to resolve prostate cancer claims put forward by plaintiff Martin Gross.
Pharmaceutical Technology
JULY 1, 2024
On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
JULY 1, 2024
At its recent June meeting, the EMA’s human medicines committee (CHMP) recommended 10 medicines for approval. Recommendations for regulatory approval The committee saw a need to give a marketing authorisation to Balversa (erdafitinib) as a treatment for adults with unresectable or metastatic urothelial carcinoma. In its meeting, the CHMP gave a positive opinion for the first nasally administered emergency treatment for allergic reactions.
Fierce Pharma
JULY 1, 2024
Fierce Pharma explored the status of the industry's noncompete clauses with experts to learn whether an intercompany transition at the highest levels can proceed without a hitch.
MedCity News
JULY 1, 2024
AI-powered solutions for opportunistic lung cancer detection using routine chest X-rays offer hope for improved early diagnosis and survival rates. The post The Role of AI in Empowering Early Lung Cancer Detection & Transforming Patient Outcomes appeared first on MedCity News.
pharmaphorum
JULY 1, 2024
Over 90% of experimental therapies that reach human trials fail to make it to market. In today’s pharmaphorum podcast, Orr Inbar, co-founder and CEO of QuantHealth, a Tel Aviv-based AI-powered clinical trial design company, discusses how advances in data and AI can help. This includes cost-effectiveness. Ever a ‘game’ of risk-and-reward, leveraging data and technology can increase clinical trial success rates, bringing down the failure rate some 20%, potentially.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
JULY 1, 2024
No one should ever learn about CKD after their kidneys have already failed. The post One Conversation Could Be All It Takes to Identify Chronic Kidney Disease appeared first on MedCity News.
pharmaphorum
JULY 1, 2024
Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outright for $1 billion.Radionetics is working on small-molecule drugs that target G protein-coupled receptors (GPCRs), a fertile source of drug targets for the pharma industry and the target of around a third of all marketed drugs but according to the company is a “largely unexplored” class for radiopharma.
MedCity News
JULY 1, 2024
K Health closed a $50 million equity funding round, which brought its total fundraising amount to $380 million and propelled the startup to a $900 million valuation. The company, which was founded in 2016, uses AI to educate patients about their symptoms and connect them to primary care. The post K Health’s Latest Funding Round Brings the Primary Care AI Startup to $380M Raised appeared first on MedCity News.
pharmaphorum
JULY 1, 2024
France's HAS agrees to fund treatment with Carthera's ultrasound device for French subjects enrolled in a glioblastoma trial.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
JULY 1, 2024
Here is a list of some of the biggest funding rounds in the payer/employer space that were announced in June. The post 5 Funding Announcements from Payer/Employer Companies In June appeared first on MedCity News.
pharmaphorum
JULY 1, 2024
NeuroSense Tx reports 12-month data with its amyotrophic lateral sclerosis therapy PrimeC, including a 43% improvement in survival
Healthcare Success
JULY 1, 2024
When my wife Clara met her new workout trainer, he asked, “What can I help you with?” She replied with a smile, “menopause.” She elaborated, “My doctor helps me with hormone therapy, and I work out five days a week at a boot camp. But I feel stuck with the way I look and feel. I want to lose fat, build muscle, and feel healthier.” When she shared this story with me, we laughed and remarked on how far things have come in recent years.
MedCity News
JULY 1, 2024
Eli Lilly is paying $140 million for the exclusive right to buy Radionetics Oncology for the price of $1 billion. The clinical-stage startup, a Crinetics Pharmaceuticals spinout, develops radiopharmaceuticals that target GPCRs overexpressed by solid tumors. The post Eli Lilly Puts $1B on the Line to Expand its Cancer Radiopharmaceuticals Prospects appeared first on MedCity News.
PharmaTech
JULY 1, 2024
EMA’s CHMP gave positive opinions on a nasal delivery for epinephrine and for a first-in-class medicine to treat pulmonary arterial hypertension, among others, including a biosimilar for treatment of autoimmune diseases.
Pharmaceutical Technology
JULY 1, 2024
Atirmociclib is a small molecule commercialized by Pfizer, with a leading Phase III program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
PharmaTimes
JULY 1, 2024
Breast cancer is the most common cancer in the UK, accounting for 15% of all cancers
Eversana Intouch
JULY 1, 2024
Repurposing content is a smart strategy that can enhance your content marketing efforts without breaking the bank. Specifically in pharmaceutical marketing, effective content repurposing can streamline efforts, maintain compliance and enhance brand engagement. In this POV, EVERSANA INTOUCH’s content strategy experts, Carrie Bolin and Jesse Brown, dive into the benefits and practical steps for effective content repurposing for your brand.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaTimes
JULY 1, 2024
The biotech company will develop novel therapeutic drugs for the treatment of fatal diseases
Pharmaceutical Technology
JULY 1, 2024
Suzetrigine is a small molecule commercialized by Vertex Pharmaceuticals, with a leading Phase III program in Post-Operative Pain.
pharmaphorum
JULY 1, 2024
Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.The results from the Vivacity-MG3 study, presented at the European Academy of Neurology (EAN), show an improvement with nipocalimab compared to placebo on activities of daily living scores that have not been seen with other FcRn inhibitors, according to J&J.
Pharmaceutical Technology
JULY 1, 2024
RL-007 is a small molecule commercialized by Atai Life Sciences, with a leading Phase II program in Diabetic Neuropathic Pain.
PharmExec
JULY 1, 2024
How pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by increasing empathy and humanity in patient interactions.
Pharmaceutical Technology
JULY 1, 2024
TauRx Pharmaceuticals has filed an application with the UK MHRA seeking approval for hydromethylthionine mesylate (HMTM) to treat Alzheimer’s.
PharmaVoice
JULY 1, 2024
As the first 10 drugs undergo price negotiations with the U.S. government, the latest spending projections reveal soon-to-be-implemented price caps will have an impact by 2027.
Pharmaceutical Technology
JULY 1, 2024
Osivelotor is a small molecule commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
243 
Let's personalize your content